Pharmaceutical company CJSC ARAY announced today that it is in active research and development phase of a new Hormone Replacement Therapy (HRT) drug, called SUSTADREN (TM), housed in Bishkek, Kyrgyz Republic.
The top quality active pharmaceutical ingredients and oils are going to be used as adjuvants in the product to ensure the best quality and compliance with international standards. Thus, all delivered ingredients and substances will comply with the pharmacopoeia grade requirements, including the British (BP) and European Pharmacopoeia (EP), as well as GMP.
The Company is looking to develop and produce a number of oral and injectable drugs of hormonal origin as housed by own GMP pharmaceutical plant in Bishkek, Kyrgyz Republic in the nearest future.
Let’s block ads! (Why?)
Quarter End AUM of $31.7 billion; Average AUM of $30.7 billion for the First Quarter…
SYDNEY--(BUSINESS WIRE)--AdvanCell, a clinical-stage radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for patients…
DUBLIN--(BUSINESS WIRE)--The "Nepal International Remittance Market Business and Investment Opportunities - Analysis by Transaction Value…
DUBLIN--(BUSINESS WIRE)--The "Thailand International Remittance Market Business and Investment Opportunities - Analysis by Transaction Value…
Functioning Like a “Central Nervous System” for Data and AI, Atlan is Crafting a Future-Proof…
DUBLIN--(BUSINESS WIRE)--The "Malaysia International Remittance Market Business and Investment Opportunities - Analysis by Transaction Value…